X4 Pharmaceuticals, Inc. (XFOR)
3.73
-0.12
(-3.12%)
USD |
NASDAQ |
Jun 10, 16:00
3.72
-0.01
(-0.27%)
After-Hours: 20:00
X4 Pharmaceuticals Total Liabilities (Quarterly) : 101.83M for March 31, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 101.83M |
| December 31, 2025 | 104.17M |
| September 30, 2025 | 101.94M |
| June 30, 2025 | 101.20M |
| March 31, 2025 | 107.07M |
| December 31, 2024 | 124.30M |
| September 30, 2024 | 118.54M |
| June 30, 2024 | 116.16M |
| March 31, 2024 | 111.15M |
| December 31, 2023 | 96.16M |
| September 30, 2023 | 105.70M |
| June 30, 2023 | 105.86M |
| March 31, 2023 | 72.73M |
| December 31, 2022 | 81.54M |
| September 30, 2022 | 51.56M |
| June 30, 2022 | 50.95M |
| March 31, 2022 | 49.91M |
| December 31, 2021 | 52.76M |
| September 30, 2021 | 51.84M |
| Date | Value |
|---|---|
| June 30, 2021 | 52.45M |
| March 31, 2021 | 54.10M |
| December 31, 2020 | 50.07M |
| September 30, 2020 | 43.42M |
| June 30, 2020 | 37.65M |
| March 31, 2020 | 34.93M |
| December 31, 2019 | 31.48M |
| September 30, 2019 | 30.43M |
| June 30, 2019 | 37.34M |
| March 31, 2019 | 33.11M |
| December 31, 2018 | 21.62M |
| September 30, 2018 | 18.00M |
| June 30, 2018 | 19.45M |
| March 31, 2018 | 20.80M |
| December 31, 2017 | 22.55M |
| September 30, 2017 | 25.59M |
| June 30, 2017 | 21.41M |
| March 31, 2017 | 32.98M |
| December 31, 2016 | 24.33M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Kyverna Therapeutics, Inc. | 61.44M |
| Arrowhead Pharmaceuticals, Inc. | 1.669B |
| Oncolytics Biotech, Inc. | 13.29M |
| Sangamo Therapeutics, Inc. | 78.92M |
| Sarepta Therapeutics, Inc. | 1.674B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 270.28M |
| Shareholders Equity (Quarterly) | 168.45M |
| Debt to Equity Ratio | 0.4586 |
| Current Ratio | 10.18 |
| Net Debt Paydown Yield | 0.04% |